Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Saved in:
Bibliographic Details
Title: Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.
Authors: Tang LB; School of Medicine, South China University of Technology, Guangzhou Higher Education Mega Centre, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Peng YL; School of Medicine, South China University of Technology, Guangzhou Higher Education Mega Centre, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Yang XR; School of Medicine, South China University of Technology, Guangzhou Higher Education Mega Centre, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Li JT; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Shantou University Medical College, Shantou, China., Lu C; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zheng MM; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Sun L; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Yang Z; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Yan LX; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Deng Y; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Chen ZH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Lv SD; School of Art, Soochow University, Suzhou, China., Zhou Q; School of Medicine, South China University of Technology, Guangzhou Higher Education Mega Centre, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Xu CR; School of Medicine, South China University of Technology, Guangzhou Higher Education Mega Centre, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Source: Translational lung cancer research [Transl Lung Cancer Res] 2025 Feb 28; Vol. 14 (2), pp. 631-638. Date of Electronic Publication: 2025 Feb 27.
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2218-6751
DOI:10.21037/tlcr-24-963